Drug Profile


Alternative Names: MK-801

Latest Information Update: 24 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Developer Merck & Co; Nonindustrial source
  • Class Analgesics; Antiepileptic drugs; Antiparkinsonians; Antivirals; Dibenzocycloheptenes; Neuroprotectants; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Epilepsy

Most Recent Events

  • 24 Nov 1998 A study has been added to the Pain pharmacodynamics section
  • 29 Oct 1998 A preclinical study has been added to the Neurological disorders pharmacodynamics section
  • 03 Jun 1997 A study has been added to the Pain pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top